Investing in the Biotech Sector: 5 Elements To Consider
March 31, 2009 at 12:10 PM EDT
When Arena Pharmaceuticals (Nasdaq: ARNA ) released positive Phase III data on its obesity drug, Lorcaserin, many people expected shares to take off. After all, the company’s press release on Monday confirmed that the drug had proven to be safe and effective. But in a classic example of just how volatile and unpredictable the…
